Rhumbline Advisers lifted its position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 3.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 34,794 shares of the biopharmaceutical company’s stock after buying an additional 1,061 shares during the period. Rhumbline Advisers owned 0.09% of Puma Biotechnology worth $4,167,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in PBYI. Sanctuary Wealth Advisors LLC purchased a new position in Puma Biotechnology during the third quarter worth approximately $4,286,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Puma Biotechnology during the third quarter worth approximately $306,000. New York State Common Retirement Fund raised its stake in Puma Biotechnology by 38.9% during the third quarter. New York State Common Retirement Fund now owns 44,792 shares of the biopharmaceutical company’s stock worth $5,364,000 after purchasing an additional 12,545 shares during the period. Sei Investments Co. purchased a new position in Puma Biotechnology during the third quarter worth approximately $256,000. Finally, Candriam Luxembourg S.C.A. raised its stake in Puma Biotechnology by 17.3% during the third quarter. Candriam Luxembourg S.C.A. now owns 57,500 shares of the biopharmaceutical company’s stock worth $6,886,000 after purchasing an additional 8,500 shares during the period. 96.05% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have weighed in on PBYI shares. Bank of America reaffirmed a “buy” rating and set a $135.00 price target (up previously from $117.00) on shares of Puma Biotechnology in a research note on Monday, October 9th. Citigroup reaffirmed a “buy” rating and set a $156.00 price target (up previously from $114.00) on shares of Puma Biotechnology in a research note on Thursday, October 5th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $131.00 price target on shares of Puma Biotechnology in a research note on Wednesday, October 4th. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 price target (down previously from $118.00) on shares of Puma Biotechnology in a research note on Thursday, August 10th. Finally, BidaskClub downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $130.67.
Shares of Puma Biotechnology Inc (NASDAQ PBYI) opened at $93.85 on Wednesday. Puma Biotechnology Inc has a 52-week low of $28.35 and a 52-week high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same period in the previous year, the company earned ($1.11) EPS. sell-side analysts predict that Puma Biotechnology Inc will post -8.19 earnings per share for the current fiscal year.
WARNING: “Puma Biotechnology Inc (PBYI) Position Boosted by Rhumbline Advisers” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/06/puma-biotechnology-inc-pbyi-position-boosted-by-rhumbline-advisers.html.
Puma Biotechnology Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.